Resource impact statement

No significant resource impact is anticipated

We do not expect this guidance to have a significant impact on resources; that is, it will be less than £1 million per year in England (or £1,800 per 100,000 population).

This is because cost modelling for the guidance indicates that, over 15 years, HF10 therapy using Senza spinal cord stimulation (SCS) has similar costs to low-frequency SCS using either a rechargable or non-rechargeable device. Additional modelling indicates that any costs incurred are below £1 million per year in England over this period.

This technology is commissioned by NHS England. Providers are NHS hospital trusts.

This page was last updated: 23 January 2019